Keywords: amgen, buys, filgrastim, rights, million, purchased, roche
Amgen buys filgrastim rights for $137 million
Article | 13 May 2002
Amgen has purchased from Roche the assets and business related to thecompanies' Neupogen/Granulokine (filgrastim) and Neulasta (pegfilgrastim) in the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
